At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
LGVN Longeveron Inc
Market Closed 04-02 16:00:00 EDT
1.07
-0.05
-4.46%
盘后1.06
-0.01-0.93%
19:59 EDT
High1.15Low1.04Vol1.20M
Open1.11D1 Closing1.12Amplitude9.82%
Mkt Cap31.33MTradable Cap26.95MTotal Shares29.28M
T/O1.31MT/O Rate4.75%Tradable Shares25.19M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Longeveron Receives Extended Nasdaq Compliance Grace Period
TIPRANKS  ·  03-26
Longeveron Receives Extended Nasdaq Compliance Grace Period
Longeveron gains Nasdaq extension; minimum bid compliance deadline moves to September 21, 2026
Reuters  ·  03-26
Longeveron gains Nasdaq extension; minimum bid compliance deadline moves to September 21, 2026
Longeveron Cancels Special Meeting, Reschedules Reverse Split Vote
TIPRANKS  ·  03-25
Longeveron Cancels Special Meeting, Reschedules Reverse Split Vote
Longeveron’s Alzheimer’s Program Faces High Late-Stage Failure Risk and Potential Pipeline Pressure
TIPRANKS  ·  03-19
Longeveron’s Alzheimer’s Program Faces High Late-Stage Failure Risk and Potential Pipeline Pressure
Longeveron Earnings Call: Pivotal Trials, Tight Cash
TIPRANKS  ·  03-19
Longeveron Earnings Call: Pivotal Trials, Tight Cash
Longeveron price target lowered to $2 from $3 at Roth Capital
TIPRANKS  ·  03-19
Longeveron price target lowered to $2 from $3 at Roth Capital
Longeveron Q4 EPS $(0.22) Beats $(0.32) Estimate, Sales $365.000K Beat $148.000K Estimate
Benzinga  ·  03-18
Longeveron Q4 EPS $(0.22) Beats $(0.32) Estimate, Sales $365.000K Beat $148.000K Estimate
Longeveron Announces 2025 Full Year Financial Results and Provides Business Update
GlobeNewswire  ·  03-18
Longeveron Announces 2025 Full Year Financial Results and Provides Business Update
Longeveron FY 2025 net loss widened 41% to USD 22.7 million as revenue fell 50% to USD 1.2 million
Reuters  ·  03-18
Longeveron FY 2025 net loss widened 41% to USD 22.7 million as revenue fell 50% to USD 1.2 million
Longeveron Braces For Q4 Results Following Recent Funding Boost
Benzinga  ·  03-18
Longeveron Braces For Q4 Results Following Recent Funding Boost
Longeveron Inc. Files Initial Beneficial Ownership Statement for CEO Stephen H. Willard
Reuters  ·  03-14
Longeveron Inc. Files Initial Beneficial Ownership Statement for CEO Stephen H. Willard
Longeveron Inc. to report full-year 2025 financial results and host conference call
Reuters  ·  03-12
Longeveron Inc. to report full-year 2025 financial results and host conference call
Longeveron closes USD 15 million private placement of shares
Reuters  ·  03-12
Longeveron closes USD 15 million private placement of shares
Press Release: Longeveron Announces Closing of Private Placement of up to $30 Million
Dow Jones  ·  03-12
Press Release: Longeveron Announces Closing of Private Placement of up to $30 Million
3 Penny Stocks to Watch Now, 3/11/26
TIPRANKS  ·  03-11
3 Penny Stocks to Watch Now, 3/11/26
Longeveron prices 6.01M shares at 52c in private placement
TIPRANKS  ·  03-10
Longeveron prices 6.01M shares at 52c in private placement
Press Release: Longeveron Announces Private Placement of up to $30 Million
Dow Jones  ·  03-10
Press Release: Longeveron Announces Private Placement of up to $30 Million
Longeveron reports Phase 2b trial results showing laromestrocel improves age-related frailty in Cell Stem Cell
Reuters  ·  02-26
Longeveron reports Phase 2b trial results showing laromestrocel improves age-related frailty in Cell Stem Cell
Longeveron® Results of Phase 2B Clinical Trial Demonstrating Stem Cell Therapy Improved Condition of Patients With Age-Related Frailty Published in Cell Stem Cell
THOMSON REUTERS  ·  02-26
Longeveron® Results of Phase 2B Clinical Trial Demonstrating Stem Cell Therapy Improved Condition of Patients With Age-Related Frailty Published in Cell Stem Cell
Longeveron Appoints New CEO Amid Cost-Cutting Initiatives
TIPRANKS  ·  02-14
Longeveron Appoints New CEO Amid Cost-Cutting Initiatives

Introduction

Company Name.
Longeveron Inc
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, a candidate in Phase 2a/b trials that is used for the treatment of alzheimer's disease, hypoplastic left heart syndrome, and aging-related frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.
Issue price:
--